D4 Receptor Inhibitor
-
Dopamine D4R antagonist-1
0 ImagesCat. No.: HY-130203CAS No.: 1379510-21-0Dopamine D4R antagonist-1 is a blood-brain barrier-permeable antagonist of dopamine D4 receptor. Dopamine D4R antagonist-1 functionally inhibits dopamine D4 receptor, exhibits only weak activity against dopamine D3 receptor, and shows no activity against dopamine D1 and D2 receptors.
-
Loxapine succinate
0 ImagesLoxapine succinate is an orally active dopamine inhibitor, 5-HT receptor antagonist and also a dibenzoxazepine anti-psychotic agent. Loxapine can also suppresses bacterial efflux pump activity and inhibit intracellular multiple-antibiotic-resistant Salmonella enterica serovar Typhimurium in macrophages.
-
Loxapine
0 ImagesLoxapine is an orally active dopamine inhibitor, 5-HT receptor antagonist and also a dibenzoxazepine anti-psychotic agent.
-
Benzquinamide hydrochloride
0 ImagesSynonyms: P2647 hydrochloride; BZQ hydrochloride; Benzoquinamide hydrochlorideBenzquinamide (P2647; BZQ; Benzoquinamide) hydrochloride is an orally active binder of dopamine receptors and adrenergic receptors. Benzquinamide hydrochloride specifically targets dopamine D2, D3, D4 receptors and α-2A, α-2B, α-2C adrenergic receptors. Benzquinamide hydrochloride regulates blood pressure and heart rate, attenuates the pressor effect of adrenaline, and exhibits activities such as antiemesis, anxiolysis, and reduction of histamine-induced bronchoconstriction. Benzquinamide hydrochloride has good safety and does not deplete serotonin or norepinephrine in the brain. Benzquinamide hydrochloride can be used in studies related to nausea/vomiting, mental disorders, anxiety states, neurosis, and psychosis.
-
Loxapine hydrochloride
0 ImagesCat. No.: HY-17390BCAS No.: 54810-23-0Loxapine hydrochloride is an orally active dopamine inhibitor, 5-HT receptor antagonist and also a dibenzoxazepine anti-psychotic agent.
-
Benzquinamide
0 ImagesBenzquinamide (P2647; BZQ; Benzoquinamide) is an orally active binder of dopamine receptors and adrenergic receptors. Benzquinamide specifically targets dopamine D2, D3, D4 receptors and α-2A, α-2B, α-2C adrenergic receptors. Benzquinamide regulates blood pressure and heart rate, attenuates the pressor effect of adrenaline, and exhibits activities such as antiemesis, anxiolysis, and reduction of histamine-induced bronchoconstriction. Benzquinamide has good safety and does not deplete serotonin or norepinephrine in the brain. Benzquinamide can be used in studies related to nausea/vomiting, mental disorders, anxiety states, neurosis, and psychosis.
